Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases

Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases

Abstract Anti‐angiogenic therapies using biological molecules that neutralize vascular endothelial growth factor‐A (VEGF‐A) have revolutionized treatment of retinal vascular diseases including age‐related macular degeneration (AMD). This study reports preclinical assessment of a strategy to enhance...

Full description

Saved in:
Bibliographic Details
Main Authors: Jörg T Regula, Peter Lundh von Leithner, Richard Foxton, Veluchamy A Barathi, Chui Ming Gemmy Cheung, Sai Bo Bo Tun, Yeo Sia Wey, Daiju Iwata, Miroslav Dostalek, Jörg Moelleken, Kay G Stubenrauch, Everson Nogoceke, Gabriella Widmer, Pamela Strassburger, Michael J Koss, Christian Klein, David T Shima, Guido Hartmann
Format: Article
Language:English
Published: Springer Nature 2016-10-01
Series:EMBO Molecular Medicine
Subjects:
age‐related macular degeneration
angiogenesis
angiopoietin‐2
Fc receptor
vascular endothelial growth factor
Online Access:https://doi.org/10.15252/emmm.201505889
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.15252/emmm.201505889

Similar Items